India’s Emcure Pharmaceuticals drew strong interest for its $234 million initial public offering (IPO) as investors bet on its slate of women’s healthcare and HIV treatments to drive growth in a high-margin market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
